tradingkey.logo

Elicio Therapeutics Inc <ELTX.OQ> expected to post a loss of 83 cents a share - Earnings Preview

ReutersMay 9, 2025 11:54 AM
  • Elicio Therapeutics Inc ELTX.OQ ELTX.O is expected to show no change in quarterly revenue when it reports results on May 13 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Elicio Therapeutics Inc is for a loss of 83 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Elicio Therapeutics Inc is $12.00​, above​ its last closing price of $5.57. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.87

-1.02

Missed

-16.6

Sep. 30 2024

-0.71

-0.73

-1.39

Missed

-90.4

Jun. 30 2024

-0.96

-0.96

-0.64

Beat

33.3​

Mar. 31 2024

-1.08

-1.09

-1.15

Missed

-5.5

​​Dec. 31 2023

-1.03

-0.78

-1.75

Missed

-122.9

Sep. 30 2023

-0.80

-0.80

-1.27

Missed

-58.7​

-2.44

-1.50

This summary was machine generated May 9 at 11:54 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI